Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system
- 14 January 2022
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 24 (4) , e3410
Abstract
Background: Mucopolysaccharidosis type I (MPS I) is an inherited disease caused by deficiency of the enzyme alpha‐l‐iduronidase (IDUA). MPS I affects several tissues, including the brain, leading to cognitive impairment in the severe form of the disease. Currently available treatments do not reach the brain. Therefore, in this study, we performed nasal administration (NA) of liposomal complexes carrying two plasmids encoding for the CRISPR/Cas9 system and for the IDUA gene targeting the ROSA26 locus, aiming at brain delivery in MPS I mice.Methods: Liposomes were prepared by microfluidization, and the plasmids were complexed to the formulations by adsorption. Physicochemical characterization of the formulations and complexes, in vitro permeation, and mucoadhesion in porcine nasal mucosa (PNM) were assessed. We performed NA repeatedly for 30 days in young MPS I mice, which were euthanized at 6 months of age after performing behavioral tasks, and biochemical and molecular aspects were evaluated.Results: Monodisperse mucoadhesive complexes around 110 nm, which are able to efficiently permeate the PNM. In animals, the treatment led to a modest increase in IDUA activity in the lung, heart, and brain areas, with reduction of glycosaminoglycan (GAG) levels in serum, urine, tissues, and brain cortex. Furthermore, treated mice showed improvement in behavioral tests, suggesting prevention of the cognitive damage.Conclusion: Nonviral gene editing performed through nasal route represents a potential therapeutic alternative for the somatic and neurologic symptoms of MPS I and possibly for other neurological disorders.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (151021/2018‐0, 408521/2017‐1)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (19/2551‐0001344‐2)
This publication has 29 references indexed in Scilit:
- Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type IPLOS ONE, 2015
- Standardization of α-L-iduronidase enzyme assay with Michaelis–Menten kineticsMolecular Genetics and Metabolism, 2014
- Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I miceMolecular Genetics and Metabolism, 2013
- Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIBPLOS ONE, 2012
- Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, NovasorbJournal of Drug Delivery, 2012
- Recombinant Encapsulated Cells Overexpressing Alpha-L-Iduronidase Correct Enzyme Deficiency in Human Mucopolysaccharidosis Type I CellsCells Tissues Organs, 2011
- Real-Time PCR to Determine Transgene Copy Number and to Quantitate the Biolocalization of Adoptively Transferred Cells from EGFP-Transgenic MiceBioTechniques, 2008
- Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic InjectionMolecular Therapy, 2008
- Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis BInternational Journal of Pharmaceutics, 2008
- α-l-Iduronidase transport in neuritesMolecular Genetics and Metabolism, 2006